


<sup>1</sup>Tramacere I, Del Giovane C, Salanti G, D'Amico R, Filippini G. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. Cochrane Database of Systematic Reviews 2015, Issue 9. Art. No.: CD011381. DOI: 10.1002/14651858.CD011381.pub2

	<b>Neurologists</b>	<b>People with MS or their relatives</b>	<b>Health information professionals</b>	<b>Policy-makers</b>
N. of reordered accesses	41	287	43	ongoing
N. completed questionnaires	22	185	18	ongoing
Type of representation reported in the questionnaire	<ul style="list-style-type: none"> <li>▪ Network plots</li> <li>▪ Table</li> <li>▪ Graph with horizontal segments</li> <li>▪ Histogram</li> </ul>	<ul style="list-style-type: none"> <li>▪ Network plot</li> <li>▪ Histogram+table</li> </ul>	<ul style="list-style-type: none"> <li>▪ Network plot+table</li> <li>▪ Histogram+table</li> </ul>	<ul style="list-style-type: none"> <li>▪ Network plot+table+histogram</li> </ul>

## Histogram




## Table

Treatment	N. of patients (over 100) who will not have relapses over 24 months of treatment	Quality of evidence
Alemtuzumab (Lemtrada)	70 [64-75]	★★★
Mitoxantrone (Novantrone)	69 [47-82]	★
Natalizumab (Tysabri)	64 [57-69]	★★★★
Fingolimod (Gilenya)	53 [47-58]	★★★
Immunoglobuline	52 [41-61]	★★★
Azatioprina (Imuran)	50 [30-54]	★
Glatiramer acetato (Copaxone)	46 [41-51]	★★★
Interferone beta 1b (Betaferon)	45 [39-50]	★
Interferone beta 1a (Rebif)	44 [38-50]	★★
Dimetil fumarato (Tecfidera)	44 [36-47]	★★★
Teriflunomide (Aubagio)	43 [33-51]	★
Laquinimod (Nerventra)*	43 [36-49]	★
Interferoni beta 1a o 1b (Avonex, Rebif o Betaferon)	42 [8-64]	★
Interferone beta 1a (Avonex)	41 [34-47]	★★
Placebo	35	-

\*Treatment in sperimental phase

## Network plot



## Graph with horizontal segments

